All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Alphabet's Verily Seeks EPA Approval to Release Sterilized Mosquitoes in California and Florida to Combat Disease

Google's parent company Alphabet is seeking EPA approval to release up to 32 million sterilized Aedes aegypti mosquitoes in California and Florida as a biological pest control method. The mosquitoes, infected with the Wolbachia bacteria, are designed to mate with wild females and produce eggs that don't hatch, thereby reducing populations of disease-spreading mosquitoes that carry viruses like dengue, Zika, and chikungunya. The project, run by Verily (Alphabet's life sciences division) through its Debug project, has already been tested in Fresno County and is now seeking broader approval. The approach is species-specific and does not involve genetic modification, making it an environmentally targeted alternative to broad-spectrum insecticides.

Sara Hashemi1mo ago4 min readenNews
Read on smithsonianmag.com

Key quotes

The company is asking the U.S. Environmental Protection Agency for permission to release millions of sterilized mosquitoes in order to fight their disease-spreading counterparts
The mosquitoes, infected with the Wolbachia bacteria, are designed to mate with wild females and produce eggs that don't hatch
The project, run by Verily (Alphabet's life sciences division) through its Debug project, has already been tested in Fresno County

From the article

The company is asking the U.S. Environmental Protection Agency for permission to release millions of sterilized mosquitoes in order to fight their disease-spreading counterparts
Continue reading on smithsonianmag.com

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.